The average life expectancy of hepatitis B minor triyang patients after standardized treatment is not much different from that of healthy people, and there is a lack of authoritative literature data to support the specific life expectancy. Hepatitis B minor triple positive refers to serum HBsAg positive, while anti-HBe positive, mostly seen in chronic hepatitis B patients, such as HBV-DNA quantitative negative, liver function is normal, in the case of standardized treatment and the average life expectancy of the normal population is not significantly different. However, if people with hepatitis B minor triple positive are not treated regularly, and at the same time combined with other risk factors, such as hepatitis C and alcoholic liver, there is a certain probability of progression to cirrhosis, liver cancer, etc., which has a significant impact on life expectancy. Hepatitis B is a treatable and preventable disease, and it is recommended that people with “small triple positive” should consult the doctor in time, standardize the treatment under the doctor’s guidance, and regularly review the liver function, viral quantification and other related tests.